Jan 2023: Nyra Medical reports issuance of a second patent 

• Second patent on Nyra's novel approach to treat mitral regurgitation was issued by the USPTO
• Issued patent provides strong coverage for Nyra's unique way of deploying the implant onto the heart valve

Nov 2022: Nyra Medical announces $20M Series A financing

• ​Financing co-led by Vensana Capital and a Large, Global Medical Device Company
• Use of Proceeds to Advance Development of a Novel Catheter-based Solution for Mitral Regurgitation

 
ATLANTA, GA, November 22, 2022: Nyra Medical, Inc., a medical device company that is developing a novel transcatheter mitral valve repair technology, today announced the closing of a $20 million Series A financing. The round was co-led by Vensana Capital and a large, global medical device company, alongside additional investors Broadview Ventures, Epidarex Capital, and the Georgia Research Alliance Venture Fund. Proceeds from the financing will be used to support Nyra’s technology through early feasibility clinical studies (Read more)